Last reviewed · How we verify
NaMFP
NaMFP is a sodium-dependent monocarboxylate transporter inhibitor that reduces cellular uptake of lactate and other monocarboxylates.
At a glance
| Generic name | NaMFP |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Monocarboxylate transporter inhibitor |
| Target | MCT (monocarboxylate transporter) |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
NaMFP inhibits monocarboxylate transporters (MCTs), which are responsible for the cellular uptake and efflux of lactate, pyruvate, and other monocarboxylates. By blocking these transporters, the drug alters cellular metabolism and lactate homeostasis, which may have therapeutic effects in conditions where lactate accumulation or metabolism plays a pathogenic role.
Approved indications
Common side effects
Key clinical trials
- Evaluation of Dentifrice Formulations to Remineralize Enamel and Dentine Subsurface Lesions in a Double-Blind In-Situ Clinical Trial (NA)
- Total Salivary Fluoride Concentration of Healthy Adult Subjects Following Toothbrushing With Different Formulations of Fluoridated Toothpastes With and Without Post-brushing Water Rinsing. (NA)
- Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity (PHASE3)
- Enamel Remineralization Potential of Dentifrices in Situ (PHASE4)
- In Situ Caries Efficacy of Fluoride Toothpastes (PHASE3)
- Evaluation of Plaque Fluid Fluoride Retention From Fluoride Toothpastes (PHASE3)
- In Situ Caries of Fluoride Toothpastes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NaMFP CI brief — competitive landscape report
- NaMFP updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI